Lunit, a leading provider of AI-powered cancer diagnostics, has partnered with VIDI Group, France’s largest private radiology network, to deploy its AI solution, Lunit INSIGHT MMG, across over 400 sites and 1,200 doctors. This partnership aims to enhance breast cancer screening efficiency and quality in France, leveraging VIDI’s extensive network and Lunit’s innovative AI technology.
Breast cancer is a global health concern, but early detection and advancements in treatment are improving survival rates. This article delves into the importance of mammography, explores the latest research on hormone replacement therapy and its link to breast cancer risk, and discusses the impact of AI and 3D mammography on detection. Additionally, it provides insights into the most common risk factors, preventative measures, and cutting-edge treatment options, including immunotherapy and targeted therapies for triple-negative breast cancer. Experts weigh in on the crucial role of genetic screening and risk-reducing strategies for women with high genetic risk.
Martha Twibanire’s experience in Montreal is one of many examples of wheelchair users being denied access to mammograms due to accessibility issues. A survey conducted by RAPLIQ, a Quebec advocacy group, revealed that 43% of clinics surveyed cannot accommodate wheelchair users. The problem persists despite efforts by the provincial government and advocacy groups to improve access. Experts emphasize the need for proper training for healthcare professionals and the inclusion of people with disabilities in decision-making to ensure equitable access to healthcare.
